Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Jazz Pharmaceuticals plc - Ordinary Shares (NQ:JAZZ)

112.15 +0.55 (+0.49%)
Streaming Delayed Price Updated: 2:59 PM EDT, Jul 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Jazz Pharmaceuticals plc - Ordinary Shares

< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
Werewolf Therapeutics Shares Jump On Cancer Product Pact With Jazz Pharma
Via Benzinga
Expert Ratings For Jazz Pharmaceuticals
Over the past 3 months, 4 analysts have published their opinion on Jazz Pharmaceuticals (NASDAQ:JAZZ) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 6, 2022
Upgrades 
Via Benzinga
Earnings Scheduled For March 1, 2022
Companies Reporting Before The Bell • Precigen (NASDAQ:PGEN) is expected to report earnings for its fourth quarter. • TG Therapeutics (NASDAQ:TGTX) is estimated... 
Via Benzinga
10 Biggest Price Target Changes For Wednesday
Raymond James reduced the price target on Intercontinental Exchange, Inc. (NYSE: ICE) from $161 to $157. Intercontinental Exchange shares rose 0.2% to $130.79 in pre-market trading. 
Via Benzinga
Why Axsome Therapeutics Stock Is Trading Higher
Axsome Therapeutics Inc (NASDAQ: AXSM) is trading higher Monday morning after the company announced it will acquire Sunosi from Jazz Therapeutics PLC (NASDAQ: JAZZ). 
Via Benzinga
Axsome Acquires Sleep Disorder Drug From Jazz Pharma, Expanding Its Neuroscience Portfolio
Axsome Therapeutics Inc (NASDAQ: AXSM) has  
Via Benzinga
The Daily Biotech Pulse: MEI Pharma Wilts On Adverse Regulatory Development, Decision Day For Zogenix, AN2 Therapeutics IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
Jazz Pharmaceuticals's Return On Capital Employed Insights
According to data from Benzinga Pro, during Q4, Jazz Pharmaceuticals's (NASDAQ:JAZZ) reported sales totaled $896.73 million. Despite a 33.09% increase in earnings, the company... 
Via Benzinga
Court Dismisses Canopy's Cannabis Patent Infringement Lawsuit Against Jazz's GW Pharma
The U.S. District Court for the Western District of Texas dismissed a lawsuit filed by Canadian cannabis giant C... 
Via Benzinga
Expert Ratings For Jazz Pharmaceuticals
Jazz Pharmaceuticals (NASDAQ:JAZZ) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total... 
Via Benzinga
Jazz Pharmaceuticals Announces Full Year And 4Q 2021 Financial Results
Jazz Pharmaceuticals plc (NASDAQ:JAZZ), a global biopharma... 
Via Benzinga
Jazz Pharmaceuticals: Q4 Earnings Insights
Jazz Pharmaceuticals (NASDAQ:JAZZ) reported its Q4 earnings results on Tuesday, March 1, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
The Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent Resolution
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Editas Gains On Resolution Of CRISPR Gene Editing Patent Case Editas Medicine... 
Via Benzinga
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first... 
Via Benzinga
This Company's 18-Month CBD Stability Achievement Could Hint Towards Expansion Goals As It Plans To Release First Commercial UST System In 2022
Photo by Kindel Media from Pexels This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. 
Via Benzinga
Does This Company's Recent CBD Breakthrough Earn It A Spot In The Guinness World Records?
Photo by CBD Infos on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. 
Via Benzinga
New Psychedelics ETF Launches On NYSE Arca
Elemental Advisors Inc. has launched its first ETF, composed of companies involved in research, development, production or use of psychedelics to address medical conditions. The PSYK ETF (NYSE: PSYK)... 
Via Benzinga
The "Cannabis 50" List For 2021 Is Out, Is Your Favorite Company On It?
MGO (Macias Gini and O’Connell LLP), a leader in accounting, tax, audit and advisory solutions for the cannabis and hemp industries has released its 3rd annual “Cannabis 50” list. 
Via Benzinga
Jim Cramer Shares His Thoughts On ArcBest, Ulta Beauty And More
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he likes ArcBest Corporation (NASDAQ: 
Via Benzinga
Zogenix Nabs $1.9 Billion Takeover As Epilepsy Drug Piques UCB Interest
The deal includes a CVS tied to Fintepla's next potential approval. 
Via Investor's Business Daily
Report: Global Cannabis Beverages Market Expected To Reach $2B By 2026
As the COVID-19 pandemic continues, the global market for cannabis beverages estimated at $799.8 million 2020, is projected to reach a revised... 
Via Benzinga
60 Biggest Movers From Yesterday
Gainers Bone Biologics Corporation (NASDAQ: BBLG) shares surged 57.1% to close at $5.39 on Monday. Zynga Inc. (NASDAQ: ZNGA) rose 40.7% to settle at $8.44 after the company... 
Via Benzinga
2022 Could be a Banner Year for Biotech Stocks as per top managers (SPRC, HOTH, NLSP, PSTV, IMMX, GNPX, NRBO)
Via AB Newswire
A Peek Into The Markets: US Stock Futures Up Ahead Of Manufacturing Report
Pre-open movers U.S. stock futures traded higher in early pre-market trade after the Dow Jones and S&P 500 closed at fresh highs on the first trading day of new year.... 
Via Benzinga
5 Stocks To Watch For January 4, 2022
Some of the stocks that may grab investor focus today are: Wall Street expects SMART Global Holdings, Inc. (NASDAQ: SGH) to report quarterly earnings at $2.00 per share on... 
Via Benzinga
Ten Biggest Weed Stories Of 2021: Big Pharma, Delta-8, Tech, Silicon Valley, MSOs, Politics And More
This article was originally published on WeedWeek and appears here with... 
Via Benzinga
5 Themes That Will Drive The Cannabis Sector Higher In 2022
2021 was a period of strong growth for the global cannabis market and we expect the cannabis sector to build on its success in 2022. 
Via Talk Markets
Jazz Pharmaceuticals Begins Enrollment For Clinical Trial To Evaluate JZP150 For Adults With PTSD
Biopharmaceutical company Jazz Pharmaceuticals plc (NASDAQ: JAZZ) announced Thursday that it has enrolled the first patient in its Phase 2 clinical trial evaluating the safety and... 
Via Benzinga
Jazz Pharmaceuticals: Debt Overview
Shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) rose by 0.8% on Wednesday. Before having a look at the importance of debt, let us look at how much debt Jazz Pharmaceuticals... 
Via Benzinga
< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.